Executed Nov 6, disclosed Nov 10. Four days.
paydirt.news/filing/246473/steven-h-stein-sold-incy
$INCY #insidertrading #stocks #trading
Executed Nov 6, disclosed Nov 10. Four days.
paydirt.news/filing/246473/steven-h-stein-sold-incy
$INCY #insidertrading #stocks #trading
Hub: https://www.merlintrader.com/incyte-incy-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=incy
Not investment advice.
Hub: https://www.merlintrader.com/incyte-incy-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=incy
Not investment advice.
All rank top 1% quality. Teva targeting $6-7B innovative revenue by 2030; Incyte in new Phase II cancer trial.
#technicalanalysis #stocks
All rank top 1% quality. Teva targeting $6-7B innovative revenue by 2030; Incyte in new Phase II cancer trial.
#technicalanalysis #stocks
Phase 3 MAESTRA-3 Cancelled - INCB123667 in 1L Maintenance Ovarian Cancer
Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study of INCB123667 plus bevacizumab in first-line maintenance ovarian cancer, which had bee…
https://biostock.app/symbols/INCY
Phase 3 MAESTRA-3 Cancelled - INCB123667 in 1L Maintenance Ovarian Cancer
Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study of INCB123667 plus bevacizumab in first-line maintenance ovarian cancer, which had bee…
https://biostock.app/symbols/INCY
• Insider: Steven H Stein, CMO & Head of Late-Stage Dev.
• Sold: 240,193 shares (about $28M)
• Price: about $118.39 a share · Nov 6
• Plan: pre-set 10b5-1 sale plan
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderSelling #Stocks
• Insider: Steven H Stein, CMO & Head of Late-Stage Dev.
• Sold: 240,193 shares (about $28M)
• Price: about $118.39 a share · Nov 6
• Plan: pre-set 10b5-1 sale plan
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderSelling #Stocks
Hub: https://www.merlintrader.com/incyte-incy-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Hub: https://www.merlintrader.com/incyte-incy-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Biggest unusual trade: 600 call contracts expiring Mar 19, $153K in premium vs 51 open interest.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Biggest unusual trade: 600 call contracts expiring Mar 19, $153K in premium vs 51 open interest.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
https://www.narrowit.com/sec/filing?cik=0000879169&accession=0001673776-26-000022&doc=xslF345X06%2Fwk-form4_1794344840.xml
#SEC #Form4 #InsiderTrading #INCY
https://www.narrowit.com/sec/filing?cik=0000879169&accession=0001673776-26-000022&doc=xslF345X06%2Fwk-form4_1794344840.xml
#SEC #Form4 #InsiderTrading #INCY
Off-exchange volume Nov 10 was 0.9x the usual, trend fading over 5 sessions.
Read the full article for the full details.
#darkpool #stocks #fintwit
Off-exchange volume Nov 10 was 0.9x the usual, trend fading over 5 sessions.
Read the full article for the full details.
#darkpool #stocks #fintwit
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations as of and for the three and nine months ended September 30, 2026 should be read in conjunct
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations as of and for the three and nine months ended September 30, 2026 should be read in conjunct
https://thepriorityreview.com/news/povorcitinib-hiscr50-week-12-stop-hs2-hidradenitis-suppurativa
https://thepriorityreview.com/news/povorcitinib-hiscr50-week-12-stop-hs2-hidradenitis-suppurativa
https://fundspec.ai/s/INCY/analysts
Stress test revenue, margin and WACC to see the real upside and downside.
https://fundspec.ai/s/INCY/analysts
Stress test revenue, margin and WACC to see the real upside and downside.
Oct 29: Q3 total revenue $1.56B (+14% y/y); 2026 net sales guidance raised.
New hub updated: www.merlintrader.com/incyte-incy-...
Oct 29: Q3 total revenue $1.56B (+14% y/y); 2026 net sales guidance raised.
New hub updated: www.merlintrader.com/incyte-incy-...